

Transfer of sialic acid in α 2-6 linkage to mannose in Man β 1-4GlcNAc and Man β 1-4GlcNAc β 1-4GlcNAc by the action of Gal β 1-4GlcNAc α 2-6-sialyltransferase

Johannes van Pelt*, Lambertus Dorland, Marinus Duran, Cornelis H. Hokke^o,
Johannis P. Kamerling^o and Johannes F.G. Vliegthart^o

University Children's Hospital, 'Het Wilhelmina Kinderziekenhuis' and ^oDepartment of Bio-Organic Chemistry, Utrecht University, Utrecht, The Netherlands

Received 15 August 1989

The disaccharide Man β 1-4GlcNAc and the trisaccharide Man β 1-4GlcNAc β 1-4GlcNAc were each incubated with CMP-NeuAc and rat liver α 2-6-sialyltransferase (CMP-NeuAc: Gal β 1-4GlcNAc α 2-6-*N*-acetylneuraminyl transferase). The resulting mixtures were fractionated by HPLC on Partisil 10 SAX, and the fractions obtained were investigated by TLC, GLC (monosaccharide analysis) and 500-MHz ¹H-NMR spectroscopy. The following products were identified: NeuAc α 2-6Man β 1-4GlcNAc and NeuAc α 2-6Man β 1-4GlcNAc β 1-4GlcNAc in yields of 4% and 27%, respectively. The sialylation of Man β 1-4GlcNAc-R by Gal β 1-4GlcNAc α 2-6-sialyltransferase contrasts the reported high specificity of this enzyme for the structural element Gal β 1-4GlcNAc of *N*-linked carbohydrate chains of glycoproteins and related oligosaccharides.

Sialyltransferase, Gal β 1-4GlcNAc α 2-6; Sialyltransferase; Sialyloligosaccharide; Mannosidosis, β -

1. INTRODUCTION

The isolation and structural characterization of oligosaccharides and glycoamino acids from urine of patients with lysosomal storage diseases has contributed considerably to the knowledge about carbohydrate chains of glycoproteins. In general, the excreted compounds in oligosaccharidoses and

glycoproteinoses can be recognized as parts of *N*-glycosidically linked carbohydrate chains, originating from incomplete lysosomal catabolism [1–3]. However, some of the identified urinary glycoconjugates in human aspartylglucosaminuria and caprine β -mannosidosis have not been described as normally occurring constituents of glycoproteins. For aspartylglucosaminuria, in addition to GlcNAc-Asn as the major compound, Gal β 1-4GlcNAc-Asn, NeuAc α 2-3/6Gal β 1-4GlcNAc-Asn and larger glycoamino acids have been reported [4–7]. In caprine β -mannosidosis urine extensions of the primary storage compounds Man β 1-4GlcNAc and Man β 1-4GlcNAc β 1-4GlcNAc with a Man β 1-4GlcNAc β 1-4 moiety have been found [8]. Recently, we have discovered NeuAc α 2-6Man β 1-4GlcNAc in human β -mannosidosis urine (unpublished results). In all these cases, the structures of the major storage products are elements of the structures of the unusual compounds. Therefore, it has been proposed that the accumulated, abun-

Correspondence address: L. Dorland, University Children's Hospital, 'Het Wilhelmina Kinderziekenhuis', Nieuwe Gracht 137, NL-3512 LK Utrecht, The Netherlands

* *Present address:* De Wever Hospital, Department of Clinical Chemistry, Henri Dunantstraat 5, NL-6419 PC Heerlen, The Netherlands

Abbreviations: NeuAc, *N*-acetylneuraminic acid; NeuAc-2-en, 2-deoxy-2,3-didehydro-*N*-acetylneuraminic acid; CMP-NeuAc, cytidine 5'-monophospho- β -*N*-acetylneuraminic acid

Enzyme: Gal β 1-4GlcNAc α 2-6-sialyltransferase (CMP-NeuAc: β -D-Gal-(1-4)- β -D-GlcNAc α -(2-6)-*N*-acetylneuraminyl transferase) (EC 2.4.99.1)

dantly occurring compounds can serve as substrates for glycosyltransferases. Our discovery of the presence of sialic acid in α 2-6 linkage to the mannose residue of $\text{Man}\beta$ 1-4GlcNAc prompted us to study the possibility of enzymatic synthesis of $\text{NeuAc}\alpha$ 2-6Man linkages by rat liver $\text{Gal}\beta$ 1-4GlcNAc α 2-6-sialyltransferase with $\text{Man}\beta$ 1-4GlcNAc and $\text{Man}\beta$ 1-4GlcNAc β 1-4GlcNAc as substrates.

2. MATERIALS AND METHODS

2.1. Materials

$\text{Man}\beta$ 1-4GlcNAc was isolated from pooled urines of two brothers with β -mannosidosis [9] by gel-permeation chromatography on Bio-Gel P-2 and repeated HPLC on Partisil 10 SAX. $\text{Man}\beta$ 1-4GlcNAc β 1-4GlcNAc, isolated from the kidneys of β -mannosidosis goats [10], was a gift of Dr M.Z. Jones (Department of Pathology, Michigan State University, East Lansing, MI, USA). The purities of the di- and trisaccharide were thoroughly checked by HPLC and 500 MHz $^1\text{H-NMR}$ spectroscopy. Rat liver $\text{CMP-NeuAc}:\beta$ -D-Gal-(1-4)- β -D-GlcNAc α -(2-6)-*N*-acetylneuraminyl transferase (EC 2.4.99.1) was obtained from Boehringer Mannheim (activity: 8 U/mg protein), and CMP-NeuAc (sodium salt) from Sigma.

2.2. Incubations

$\text{Man}\beta$ 1-4GlcNAc (0.8 mg) and $\text{Man}\beta$ 1-4GlcNAc β 1-4GlcNAc (1.0 mg) were each dissolved in 1.0 ml of 0.2 M Tris-maleate buffer, pH 6.7/glycerol (4:1, v/v), containing 1.0 mg bovine serum albumin, and 2.5 mg CMP-NeuAc was added. Each mixture was incubated with 50 mU (25 μ l) α 2-6-sialyltransferase at 37°C. To follow the course of reaction, aliquots (20 μ l) of the $\text{Man}\beta$ 1-4GlcNAc and $\text{Man}\beta$ 1-4GlcNAc β 1-4GlcNAc incubations were taken for HPLC-analysis at $t = 0, 1, 2, 4, 6, 24$ h and at $t = 0, 1, 3, 6, 24$ h, respectively. The incubations were stopped after 24 h by cooling to 0°C, and the various components were fractionated preparatively by HPLC. The HPLC-subfractions were desalted on a Bio-Gel P-2 column (50 \times 1 cm, Bio-Rad) using water as eluent.

2.3. Chromatographic procedures

HPLC-analysis was performed isocratically on a Partisil 10 SAX column (250 \times 4.6 mm, Whatman) using acetonitrile/30 mM KH_2PO_4 , pH 4.9, as elution system (75:25, v/v, in case of $\text{Man}\beta$ 1-4GlcNAc incubation and 70:30, v/v, in case of $\text{Man}\beta$ 1-4GlcNAc β 1-4GlcNAc incubation) at a flow rate of 2.0 ml/min. The LKB 2150-HPLC system was connected to a diode array detector (Rapid Spectral Detector 2140, LKB) and an Olivetti M240 computer.

TLC was performed on Merck DC Alufolien and Plastikfolien Kieselgel 60 (0.2 mm, 10 \times 10 cm) eluted two times with 1-propanol/acetic acid/water (85:1:15, v/v). The TLC plates were stained with orcinol/ H_2SO_4 to detect hexose-




Fig.1. HPLC profiles of the $\text{Man}\beta$ 1-4GlcNAc β 1-4GlcNAc incubation mixture on a Partisil 10 SAX column, eluted with acetonitrile/30 mM KH_2PO_4 , pH 4.9 (70:30, v/v). The insert shows the formation of product with time ($t = 1, 3, 6$ and 24 h) and the complete profile represents the preparative HPLC profile obtained after 24 h. Subfraction B was collected as indicated. Due to anomerization, substrate as well as subfraction B occur as two peaks.

Table 1

Monosaccharide analysis data of the HPLC-subfractions **A** and **B**, representing the products of Man β 1-4GlcNAc and Man β 1-4GlcNAc β 1-4GlcNAc incubations, respectively

| Monosaccharide | A | B |
|----------------------------|-----|-----|
| Man ^a | 1.0 | 1.0 |
| GlcNAc | 1.0 | 2.0 |
| NeuAc | 0.9 | 1.1 |
| Amount (nmol) ^b | 84 | 470 |
| Yield (%) ^c | 4 | 27 |

^a The molar ratios are relative to Man = 1.00

^b Amount indicates the total amount of Man in the subfractions

^c Yield indicates the amount of Man present in the subfractions relative to the amounts of substrates used

containing compounds and with orcinol/FeCl₃/HCl to visualize sialic acid-containing compounds [11].

Monosaccharide analysis was performed by GLC. The trimethylsilylated methyl glycosides were analyzed on a

capillary CP-Sil 5 WCOT fused silica column (25 × 0.32 mm, 0.11 μm film thickness, Chrompack) after methanolysis, *N*-reacetylation and trimethylsilylation [12].

2.4. 500 MHz ¹H-NMR spectroscopy

500 MHz ¹H-NMR spectroscopy was carried out on a Bruker AM-500 spectrometer (Department of Chemistry, Utrecht University) at probe temperatures of 27, 32 and 37°C. Before recording ¹H-NMR spectra in ²H₂O, the samples were repeatedly exchanged in ²H₂O (99.96 atom% ²H, Aldrich) with intermediate lyophilization [13]. Chemical shifts (δ) are given relative to internal acetone (δ = 2.225 ppm).

3. RESULTS

Incubation of Man β 1-4GlcNAc with CMP-NeuAc in the presence of rat liver α 2-6-sialyl-transferase gave rise to a small decrease of the amount of acceptor with time, as observed by HPLC. Due to the complexity of the HPLC elution profile, product formation was not directly deducible. On the other hand, for the Man β 1-4GlcNAc β 1-4GlcNAc incubation, the

Table 2

¹H-Chemical shift values of structural reporter group protons of the constituent monosaccharides of the HPLC-subfractions **A** and **B**, together with those of reference compounds Man β 1-4GlcNAc [15] and Man β 1-4GlcNAc β 1-4GlcNAc

| Residue | Reporter group | Chemical shifts in ^a | | | |
|-----------------------|----------------|---------------------------------|-----------------------|--|-----------------------|
| | | Man β 1-4GlcNAc | A | Man β 1-4GlcNAc- β 1-4GlcNAc | B |
| GlcNAc-1 ^b | H-1 α | – | – | 5.189 | 5.195 |
| | H-1 β | – | – | 4.696 | 4.696 |
| | NAc | – | – | 2.039 | 2.039/38 ^c |
| GlcNAc-2 | H-1 α | 5.211 | 5.207 | – | – |
| | H-1 β | 4.724 | 4.736 | 4.610/01 ^c | 4.628/19 ^c |
| | NAc | 2.044 | 2.062 | 2.064 | 2.087/86 ^c |
| Man | H-1 | 4.769 | 4.751 | 4.764 | 4.747 |
| | H-2 | 4.071/61 ^d | 4.067/60 ^d | 4.060 | 4.059 |
| | H-5 | 3.438 | 3.509 | 3.420 | 3.507 |
| NeuAc | H-3a | – | 1.724/20 ^d | – | 1.714 |
| | H-3e | – | 2.697 | – | 2.694 |
| | NAc | – | 2.033 | – | 2.033 |

^a Chemical shifts (δ) are given for neutral solutions at 27°C (**B**), 32°C (Man β 1-4GlcNAc β 1-4GlcNAc) or 37°C (**A** and Man β 1-4GlcNAc), in ppm downfield from internal sodium 4,4-dimethyl-4-silapentane-1-sulfonate in ²H₂O acquired at 500 MHz, but were actually measured by reference to internal acetone (δ 2.225 ppm)

^b GlcNAc-1 is the GlcNAc residue at the reducing terminus of Man β 1-4GlcNAc β 1-4GlcNAc

^c Two signals were observed due to anomerization of GlcNAc-1 H-1

^d Two signals were observed due to anomerization of GlcNAc-2 H-1

HPLC profiles at $t = 0, 1, 3, 6$ and 24 h clearly showed the decrease of substrate and the formation of product with time (fig.1). In both incubations the amount of CMP-NeuAc gradually decreased until almost zero after 24 h, which is mainly caused by non-enzymatic cleavage of CMP-NeuAc into CMP and NeuAc-2-en [14]. A similar decrease of CMP-NeuAc was also observed in control experiments. After 24 h both incubation mixtures were separated by preparative HPLC into subfractions (fig.1), which were checked for the

presence of NeuAc-containing oligosaccharides by monosaccharide analyses. Each incubation gave one NeuAc-positive HPLC-subfraction, denoted **A** and **B**, respectively. Monosaccharide analysis of **A** and **B** (table 1) revealed the presence of NeuAc, Man and GlcNAc, in molar ratios of $0.9:1.0:1.0$ and $1.1:1.0:2.0$, respectively. TLC of subfraction **A** showed a sialic acid/hexose-containing band, which migrated to the same position as NeuAc α 2-6Man β 1-4GlcNAc, isolated from human β -mannosidosis urine. The compound pre-




Fig.2. 500 MHz ^1H -NMR spectra of subfractions **A** (a) and **B** (b), obtained by incubation of Man β 1-4GlcNAc and Man β 1-4GlcNAc β 1-4GlcNAc with Gal β 1-4GlcNAc α 2-6-sialyltransferase, recorded in $^2\text{H}_2\text{O}$ at 37°C and 27°C , respectively. The relative intensity scale of the *N*-acetyl regions differ from that of the other parts of the spectra as indicated. Spinning side bands are indicated by * and impurities by \emptyset .

sent in subfraction **B** showed a sialic acid/hexose-containing band below that of $\text{Man}\beta 1\text{-4GlcNAc}\beta 1\text{-4GlcNAc}$ on TLC.

Subfractions **A** and **B** were subjected to 500-MHz $^1\text{H-NMR}$ spectroscopy. The chemical shift data of the structural-reporter groups are given in table 2, together with those of $\text{Man}\beta 1\text{-4GlcNAc}$ and $\text{Man}\beta 1\text{-4GlcNAc}\beta 1\text{-4GlcNAc}$. The NMR spectrum of **A** (fig.2a) was identical to that of $\text{NeuAc}\alpha 2\text{-6Man}\beta 1\text{-4GlcNAc}$, isolated from human β -mannosidosis urine. The $\alpha 2\text{-6}$ -linked NeuAc residue in **A** is characterized by the acetamido, H-3a and H-3e signals at δ 2.033, 1.724/20 and 2.697, respectively. As compared to $\text{Man}\beta 1\text{-4GlcNAc}$ [15], the attachment of NeuAc at C-6 of Man gives rise to significant chemical shift alterations for Man H-1 ($\Delta\delta$ -0.018) and Man H-5 ($\Delta\delta$ $+0.071$) and for the NAc signal of GlcNAc ($\Delta\delta$ $+0.018$). Based on the $^1\text{H-NMR}$ data, the monosaccharide analysis and the TLC behaviour, the structure of the compound in subfraction **A** was proved to be $\text{NeuAc}\alpha 2\text{-6Man}\beta 1\text{-4GlcNAc}$. This compound was synthesized in a yield of 4%.

The $^1\text{H-NMR}$ spectrum of subfraction **B** (fig.2b) revealed a similar set of NeuAc values as observed for NeuAc in subfraction **A** (acetamido, δ 2.033; H-3a, δ 1.714; H-3e, δ 2.694). Comparison of the $^1\text{H-NMR}$ data of **A** and **B** showed the same shift effects for Man H-1 ($\Delta\delta$ -0.017), Man H-5 ($\Delta\delta$ $+0.087$) and the acetamido group of GlcNAc-2 ($\Delta\delta$ $+0.023/0.022$). The remaining structural reporter groups were hardly influenced, except GlcNAc-2 H-1, which shifted downfield ($\Delta\delta$ $+0.018$). Based on the $^1\text{H-NMR}$ data and the monosaccharide analysis, the structure of the compound in subfraction **B** was proved to be $\text{NeuAc}\alpha 2\text{-6Man}\beta 1\text{-4GlcNAc}\beta 1\text{-4GlcNAc}$. The novel compound was formed in a yield of 27%.

4. DISCUSSION

This paper gives detailed information on the *in vitro* biosynthesis of $\text{NeuAc}\alpha 2\text{-6Man}\beta 1\text{-4GlcNAc}$ and $\text{NeuAc}\alpha 2\text{-6Man}\beta 1\text{-4GlcNAc}\beta 1\text{-4GlcNAc}$ from $\text{Man}\beta 1\text{-4GlcNAc}$ and $\text{Man}\beta 1\text{-4GlcNAc}\beta 1\text{-4GlcNAc}$, respectively, using CMP-NeuAc as glycosyl donor in the presence of rat liver $\alpha 2\text{-6}$ -sialyltransferase. Up to now the latter enzyme has shown to be highly specific for the sequence $\text{Gal}\beta 1\text{-4GlcNAc}$ as part of *N*-linked carbohydrate

chains of glycoproteins and related oligosaccharides, and adds NeuAc exclusively to the 6-position of galactose. Typical relative rates are: $\text{Gal}\beta 1\text{-4GlcNAc} = 1.00$ ($K_m = 1.62$ mM) and $\text{Gal}\beta 1\text{-4Glc} = 0.01$ ($K_m = 129$ mM), while $\text{Gal}\beta 1\text{-6GlcNAc}$ and $\text{Gal}\beta 1\text{-3GlcNAc}$ showed no reaction. The $\alpha 2\text{-6}$ -sialyltransferase does not recognize $\text{Gal}\beta 1\text{-6GalNAc}$, $\text{Gal}\beta 1\text{-3GalNAc}$, GlcNAc-R ($R =$ oligosaccharide), $\text{Gal}\beta 1\text{-3GalNAc-Ser/Thr}$, GalNAc-Ser/Thr or other carbohydrates which are *O*-linked to glycoproteins, as substrates [16–18]. However, our experiments show that $\text{Man}\beta 1\text{-4GlcNAc}$ and $\text{Man}\beta 1\text{-4GlcNAc}\beta 1\text{-4GlcNAc}$ can also serve as substrates, indicating a broader specificity for the enzyme, or less probable another sialyltransferase with this new substrate specificity is present in the commercial enzyme preparation.

This finding explains the accumulation of $\text{NeuAc}\alpha 2\text{-6Man}\beta 1\text{-4GlcNAc}$ in addition to the major storage product $\text{Man}\beta 1\text{-4GlcNAc}$ in human β -mannosidosis. The presence of NeuAc $\alpha 2\text{-6}$ -linked to a mannose residue instead of a galactose residue suggests that the axial/equatorial position of the hydroxyl groups at C-2 and C-4 of the terminal sugar are of minor importance for the effectivity of the $\alpha 2\text{-6}$ -sialyltransferase reaction. However, the presence of a $\beta 1\text{-4GlcNAc}$ moiety seems to be preferable for $\alpha 2\text{-6}$ -sialyltransferase action.

Acknowledgements: The authors thank Dr M.Z. Jones, Department of Pathology, Michigan State University, East Lansing, MI, USA, for providing the trisaccharide $\text{Man}\beta 1\text{-4GlcNAc}\beta 1\text{-4GlcNAc}$ and Drs P. de Waard for recording the $^1\text{H-NMR}$ spectra. Dr H. Schachter (The Hospital for Sick Children, Toronto, Ont., Canada; Visiting Professor on the Donders chair at Utrecht University) is gratefully acknowledged for critically reading the manuscript.

REFERENCES

- [1] Strecker, G. and Montreuil, J. (1979) *Biochimie* (Paris) 61, 1199–1246.
- [2] Strecker, G. (1981) in: *Lysosomes and Lysosomal Storage Disease* (Callahan, J.W. and Lowden, J.A. eds) pp.95–114, Raven, New York.
- [3] Warner, T.G. and O'Brien, J.S. (1983) *Annu. Rev. Genet.* 17, 395–441.
- [4] Lundblad, A., Masson, P.K., Nordén, N.E., Svensson, S., Öckerman, P.-A. and Palo, J. (1976) *Eur. J. Biochem.* 67, 209–214.
- [5] Sugahara, K., Funakoshi, S., Funakoshi, I., Aula, P. and Yamashina, I. (1976) *J. Biochem. (Tokyo)* 80, 195–201.

- [6] Sugahara, K., Akasaki, M., Funakoshi, I., Aula, P. and Yamashina, I. (1977) *FEBS Lett.* 78, 284–286.
- [7] Michalski, J.-C. (1984) Thesis, University of Lille, France, pp.237–248.
- [8] Matsuura, F. and Jones, M.Z. (1985) *J. Biol. Chem.* 260, 15239–15245.
- [9] Dorland, L., Duran, M., Hoefnagels, F.E.T., Breg, J.N., Fabry de Jonge, H., Cransberg, K., Van Sprang, F.J. and Van Diggelen, O.P. (1988) *J. Inher. Met. Dis.* 11, suppl.2, 255–258.
- [10] Matsuura, F., Laine, R.A. and Jones, M.Z. (1981) *Arch. Biochem. Biophys.* 211, 485–493.
- [11] Schauer, R. (1978) *Methods Enzymol.* 50C, 64–89.
- [12] Kamerling, J.P. and Vliegthart, J.F.G. (1982) *Cell Biol. Monogr.* 10, 95–125.
- [13] Vliegthart, J.F.G., Dorland, L. and Van Halbeek, H. (1983) *Adv. Carbohydr. Chem. Biochem.* 41, 209–374.
- [14] Beau, J.-M., Schauer, R., Haverkamp, J., Kamerling, J.P., Dorland, L. and Vliegthart, J.F.G. (1984) *Eur. J. Biochem.* 140, 203–208.
- [15] Dorland, L., Van Rhee, A.M., Van Pelt, J., Duran, M., Dallinga, J., Heerma, W. and De Waard, P. (1988) *Glycoconj. J.* 5, 215–219.
- [16] Weinstein, J., De Sousa-e-Silva, U. and Paulson, J.C. (1982) *J. Biol. Chem.* 257, 13835–13844.
- [17] Weinstein, J., De Sousa-e-Silva, U. and Paulson, J.C. (1982) *J. Biol. Chem.* 257, 13845–13853.
- [18] Schriewer, H., Berge, P.-G. and Wilhelm, A. (1983) in: *Methods of Enzymatic Analysis*, 3rd edn, vol.3 (Bergmeyer, H.U. ed.) pp.407–414, VCH, Weinheim, FRG.